Marine Staurosporine Analogues: Activity and Target Identification in Triple-Negative Breast Cancer

Mar Drugs. 2024 Oct 5;22(10):459. doi: 10.3390/md22100459.

Abstract

Triple-negative breast cancer (TNBC) is a subtype of breast cancer with high mortality and drug resistance and no targeted drug available at present. Compound 4, a staurosporine alkaloid derived from Streptomyces sp. NBU3142 in a marine sponge, exhibits potent anti-TNBC activity. This research investigated its impact on MDA-MB-231 cells and their drug-resistant variants. The findings highlighted that compound 4 inhibits breast cancer cell migration, induces apoptosis, arrests the cell cycle, and promotes cellular senescence in both regular and paclitaxel-resistant MDA-MB-231 cells. Additionally, this study identified mitogen-activated protein kinase kinase kinase 11 (MAP3K11) as a target of compound 4, implicating its role in breast tumorigenesis by affecting cell proliferation, migration, and cell cycle progression.

Keywords: MAP3K11; apoptosis; cancer stem cells; cell migration; staurosporine analogue; triple-negative breast cancer.

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Apoptosis* / drug effects
  • Cell Line, Tumor
  • Cell Movement* / drug effects
  • Cell Proliferation* / drug effects
  • Cellular Senescence / drug effects
  • Drug Resistance, Neoplasm / drug effects
  • Female
  • Humans
  • MAP Kinase Kinase Kinases / antagonists & inhibitors
  • MAP Kinase Kinase Kinases / metabolism
  • Porifera
  • Staurosporine* / analogs & derivatives
  • Staurosporine* / pharmacology
  • Streptomyces
  • Triple Negative Breast Neoplasms* / drug therapy
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Staurosporine
  • Antineoplastic Agents
  • MAP Kinase Kinase Kinases